Literature DB >> 12206990

Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts.

Solène Grazide1, Nicolas Maestre, Robert Jan Veldman, Christine Bezombes, Stéphane Maddens, Thierry Levade, Guy Laurent, Jean-Pierre Jaffrézou.   

Abstract

Induction of apoptosis by DNA-damaging agents such as 1-beta-D-arabinofuranosylcytosine (Ara-C) includes the activation of Lyn protein tyrosine kinase. We have previously established that Ara-C-induced activation of Lyn results in its binding to a neutral sphingomyelinase (SMase) and is requisite for its stimulation and the induction of apoptosis in U937 cells. However, the spacio-temporal organization of these events is unclear. This study demonstrates that part of the total cellular SMase activity is sequestered in sphingomyelin-enriched plasma membrane microdomains (rafts). Under Ara-C and daunorubicin (DNR) treatment, Lyn is rapidly activated and translocated into rafts. The compartmentalization of Lyn (as well as neutral SMase activation and apoptosis) induced by these drugs was blocked by the tyrosine kinase inhibitor herbimycin A and raft disruption. In conclusion, this study establishes that DNA-damaging agents such as Ara-C and DNR rapidly induce Lyn activation and its translocation into membrane rafts. This, in turn leads to neutral SMase activation and raft-associated sphingomyelin hydrolysis with the concomitant generation of the proapoptotic lipid second messenger, ceramide. The apparent topological partitioning between DNA damage and apoptosis signaling (integrated into specialized plasma membrane domains) is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12206990     DOI: 10.1096/fj.01-0794fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

1.  7-ketocholesterol incorporation into sphingolipid/cholesterol-enriched (lipid raft) domains is impaired by vitamin E: a specific role for alpha-tocopherol with consequences on cell death.

Authors:  Marie-Charlotte Royer; Stéphanie Lemaire-Ewing; Catherine Desrumaux; Serge Monier; Jean-Paul Pais de Barros; Anne Athias; Dominique Néel; Laurent Lagrost
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

2.  Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Authors:  Li-Pin Kao; Samy A F Morad; Traci S Davis; Matthew R MacDougall; Miki Kassai; Noha Abdelmageed; Todd E Fox; Mark Kester; Thomas P Loughran; Jose' L Abad; Gemma Fabrias; Su-Fern Tan; David J Feith; David F Claxton; Sarah Spiegel; Kelsey H Fisher-Wellman; Myles C Cabot
Journal:  J Lipid Res       Date:  2019-07-30       Impact factor: 5.922

Review 3.  Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg?

Authors:  Wing-Kee Lee; Richard N Kolesnick
Journal:  Cell Signal       Date:  2017-07-04       Impact factor: 4.315

Review 4.  Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.

Authors:  Johnson Ung; Su-Fern Tan; Todd E Fox; Jeremy J P Shaw; Luke R Vass; Pedro Costa-Pinheiro; Francine E Garrett-Bakelman; Michael K Keng; Arati Sharma; David F Claxton; Ross L Levine; Martin S Tallman; Myles C Cabot; Mark Kester; David J Feith; Thomas P Loughran
Journal:  Blood Rev       Date:  2022-04-09       Impact factor: 10.626

5.  A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity.

Authors:  Ana Catarina Alves; Daniela Ribeiro; Miguel Horta; José L F C Lima; Cláudia Nunes; Salette Reis
Journal:  J R Soc Interface       Date:  2017-08       Impact factor: 4.118

6.  Integrin-associated Lyn kinase promotes cell survival by suppressing acid sphingomyelinase activity.

Authors:  Daria A Chudakova; Youssef H Zeidan; Brian W Wheeler; Jin Yu; Sergei A Novgorodov; Mark S Kindy; Yusuf A Hannun; Tatyana I Gudz
Journal:  J Biol Chem       Date:  2008-08-05       Impact factor: 5.157

Review 7.  Killing tumours by ceramide-induced apoptosis: a critique of available drugs.

Authors:  Norman S Radin
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

Review 8.  Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids.

Authors:  Delphine Milhas; Christopher J Clarke; Yusuf A Hannun
Journal:  FEBS Lett       Date:  2009-10-24       Impact factor: 4.124

Review 9.  Novel chemotherapeutic drugs in sphingolipid cancer research.

Authors:  Daniel Canals; Yusuf A Hannun
Journal:  Handb Exp Pharmacol       Date:  2013

Review 10.  The regulatory function of mixed lineage kinase 3 in tumor and host immunity.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Basabi Rana; Ajay Rana
Journal:  Pharmacol Ther       Date:  2020-10-09       Impact factor: 13.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.